## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($191.97)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Becton, Dickinson and Company to effect additional $10M share repurchase program**
- Source: MSN | 20260105T000804 | Somewhat-Bullish | Relevance: 100%
- Becton, Dickinson and Company (BDX) has announced an additional share repurchase program, authorizing the company to buy back up to $10 million in common stock. This new authorization follows a previously expired $10 million program and reflects the company's strategy to return capital to shareholders. The company plans to execute these repurchases through open market or privately negotiated transactions.

**2. Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $207.00 at Bank of America**
- Source: MarketBeat | 20260105T134557 | Somewhat-Bullish | Relevance: 100%
- Bank of America has increased its price target for Becton, Dickinson and Company (NYSE:BDX) shares to $207.00 from $190.00, while maintaining a "neutral" rating. This new target implies a potential upside of 6.3% from the stock's previous closing price. The consensus among analysts remains a "Hold" rating with an average target price of $207.18.

**3. BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial**
- Source: PR Newswire | 20260105T120807 | Bullish | Relevance: 100%
- BD has achieved a significant milestone with the first prophylactic Phasix™ Mesh laparotomy reinforcement case in Greece, following its expanded indication for hernia prevention in Europe. Concurrently, the PREVENT clinical trial, evaluating the mesh in both Europe and the U.S., has enrolled over 85% of its target population, aiming to provide robust evidence for prophylactic bioabsorbable mesh placement to reduce incisional hernias. This initiative underscores BD's commitment to improving patient outcomes and reducing healthcare costs associated with incisional hernias.

**4. JARISLOWSKY FRASER Ltd Cuts Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20260103T143133 | Neutral | Relevance: 100%
- JARISLOWSKY FRASER Ltd reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 0.7% in the third quarter, now holding 935,130 shares valued at approximately $175 million. The medical instruments supplier has a consensus "Hold" rating from analysts with an average price target of $205.64, although Jefferies recently upgraded its rating to "Buy" with a $220 price target. Becton, Dickinson also increased its quarterly dividend to $1.05 per share, representing a 2.2% yield.

**5. Financiere des Professionnels Fonds d investissement inc. Has $21.11 Million Stake in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20260103T140934 | Somewhat-Bullish | Relevance: 100%
- Financiere des Professionnels Fonds d’investissement inc. significantly increased its stake in Becton, Dickinson and Company (BDX) by 11.3%, now holding 112,760 shares valued at $21.11 million, making BDX its 14th largest holding. The article highlights Becton, Dickinson's recent dividend boost to $1.05 per quarter and provides an overview of analyst ratings, with a consensus "Hold" rating and a target price of $205.64. It also details recent insider stock sales and financial performance metrics for the medical technology company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | B of A Securiti | $207 | $190 | +9% |
| 2025-12-17 | RBC Capital | $210 | $202 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | B of A Securiti | main | Neutral |
| 2025-12-17 | RBC Capital | main | Sector Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 12 ($0.04M) |
| Sells | 8 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (2 raises, avg +6%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.8B |
| Beta | 0.26 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 12.5 |
| Current P/E | 13.3 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.3% to 1.4% (+1.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.6pp (needs >4.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.43% (CS: 57) | Neutral |
| RSI_14 | 59.9 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 1.016x | Above |
| vs SMA50 | 1.043x | Above |
| vs SMA200 | 1.056x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $198.93
- **Stop Loss:** $191.97 (3.5% risk)
- **Target:** $212.85 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 123
- **Position Value:** $24,468.39
- **Portfolio %:** 24.47%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*